Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy

2018 ◽  
Vol 172 (3) ◽  
pp. 619-626 ◽  
Author(s):  
Seung Hyuck Jeon ◽  
Kyung Hwan Shin ◽  
Jin Ho Kim ◽  
Kyubo Kim ◽  
In Ah Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Locoregional Recurrence ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

scholarly journals Relations of Human Epidermal Growth Factor Receptor 2 (HER2) Expression and E-Cadherin (CDH1) Expression in Breast Cancer Patients

Biomedika ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 1-8
Author(s):  
Martga Bella Rahimi ◽  
Wirsma Arif Harahap ◽  
Yanwirasti Yanwirasti
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

The aim of this study is to analyze the relations of Human Epidermal Growth Factor Receptor 2 (HER2) expression and E-Cadherin (CDH1) expression in breast cancer patients. To date, the synergistic effect of this CDH1/HER2 complex is not well clarified. The design of this study was cross-sectional with a total sample of 56 formalin-fixed paraffin tissue blocks that had been examined for HER2. Furthermore, CDHI expression was examined using the Immunohistochemistry staining technique with the Labeled Streptavidin Biotin Complex (LSAB) method. Bivariate analysis was performed using the Spearman correlation test with abnormally distributed data (p>0.05). Of the 56 data on breast cancer patients, most of the patients (87.5%) were diagnosed at the age of ≥40 years. The majority of cancer staging was IIIB, which was 42.9% of the total 56 patients. The study results shows that 80.0% of HER2-positive patients were in the strong CDH1 group. From these data, there is evidence of correlation between HER2 expression and CDH1 expression in breast cancer patients, however this correlation was not significant (p>0.05).

scholarly journals Prognostic significance of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in patients with breast cancer

2017 ◽  
Vol 70 (1-2) ◽  
pp. 5-11
Author(s):  
Kosta Zdravkovic ◽  
Jelena Zdravkovic ◽  
Momcilo Stosic ◽  
Igor Stojanovic ◽  
Rasic Popovic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Early Stage ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Introduction. The importance of understanding the biology of breast cancer is increasing and the determination of certain phenotypic characteristics of malignant cells, especially estrogen, progesterone and human epidermal growth factor receptor 2 expression, became a standard evaluation procedure in breast cancer patients, in order to provide prognostic information and best therapeutic options. Material and methods. This study included a total of 206 patients, all treated and followed up in the Daily Chemotherapy Hospital of the Health Center Vranje. Estrogen, progesterone and human epidermal growth factor receptor 2 statuses were evaluated in all patients to assess their potential impact on the progression-free and overall survival. Results. Two-thirds of patients were diagnosed at the early stage of the disease. Ductal carcinoma was the most common histological type. Patients with early stage breast cancer, with hormone-receptor positive and human epidermal growth factor receptor 2 negative tumors, had a significantly longer progression-free survival. Conclusion. Hormone-receptor and human epidermal growth factor receptor 2 status evaluation is still of great clinical importance with a reliable prognostic value in breast cancer patients.

Expression Analyses of Epidermal Growth Factor Receptor and HER-2/neu: No Advantage of Prediction of Recurrence or Survival in Breast Cancer Patients

Oncology ◽  
1996 ◽  
Vol 53 (6) ◽  
pp. 441-447 ◽  
Author(s):  
Matthias W. Beckmann ◽  
Dieter Niederacher ◽  
Gero Massenkeil ◽  
Boris Tutschek ◽  
Andreas Beckmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document